Human CD73/NT5E protein, His tag (Animal-Free) | PRP2036

Human CD73/NT5E protein, His tag (Animal-Free) | PRP2036 | Gentaur UK, US & Europe Distribution

Product Category: Cytology

Application: Cytokines

Product Type: Cytokines (Animal-Free)

Sequence: Amino acid sequence derived from human CD73 protein (NP_002517.1, Met1-Lys547) was expressed with a polyhistidine tag at the C-terminus.

Activity: N/A

protein Lenght: The recombinant human CD73 protein consists of 528 amino acids and predicts a molecular mass of 59 kD.The apparent molecular mass of the human CD73 is approximately 70 kDa in SDS-PAGE under reducing conditions due to glycosylation.

Preparation: HEK 293 Cells

Purity: >95% as determined by SDS-PAGE

Formulation: Lyophilized from sterile PBS, pH 7.4.

Kit Component: N/A

Features & Benefits : Endotoxin: < 1 EU per µg of the protein as determined by the LAL method.

Molecular Weight: 59kDa

Usage Note: Always centrifuge tubes before opening. It is recommended to reconstitute the lyophilized human CD73 protein in the buffer which we provide not less than 100 µg/mL, which can then be further diluted to other aqueous solutions.

Storage Conditions: Lyophilized Human CD73/NT5E protein, His tag (Animal-Free) should be stored desiccated below -20°C. Upon reconstitution, the protein should be stored at 4°C between 2-7 days and for future use below -20°C. For long term storage it is recommended to add a carrier protein (0.115% HSA or BSA) . Please prevent freeze-thaw cycles.

Shipping: The product is shipped at ambient temperature.

Background: CD73 (ecto-5'-nucleotidase) is a novel immunoinhibitory protein that plays a key role for tumor growth and metastasis. Its main function is to convert extracellular ATP to immunosuppressive adenosine in concert with CD39 in normal tissues to limit excessive immune response. However, tumors take advantage of the CD73-mediated adenosinergic mechanism to protect them from immune attack. In particular, inducible expression of CD73 along with other adenosinergic molecules on both cancer cells and host cells sustains immunosuppressive tumor microenvironment by affecting multiple aspects of the immune response. Owing to its multifaceted capacity to tumor promotion as an emerging immune checkpoint, CD73 is an ideal therapeutic target for cancer treatment especially in combination with conventional therapy and/or other immune checkpoint inhibitors.

Alternative Names: 5' nucleotidase (CD73) ; 5'-NT; 5-NT; 5'-Nucleotidase; 5'-nucleotidase, ecto (CD73) ; CD73 antigen; CD73; E5NT; EC 3.1.3.5; ecto-5'-nucleotidase; eN; eNT; NT; NT55'-nucleotidase; NT5E; NTE; Purine 5-Prime-Nucleotidase

Search Names: 5' nucleotidase (CD73) ; 5'-NT; 5-NT; 5'-Nucleotidase; 5'-nucleotidase, ecto (CD73) ; CD73 antigen; CD73; E5NT; EC 3.1.3.5; ecto-5'-nucleotidase; eN; eNT; NT; NT55'-nucleotidase; NT5E; NTE; Purine 5-Prime-Nucleotidase

Tag: CD73/NT5E